Literature DB >> 15942677

Direct effect of plasma permeability factors from patients with idiopatic FSGS on nephrin and podocin expression in human podocytes.

Sophie Doublier1, Luca Musante, Enrico Lupia, Giovanni Candiano, Tiziana Spatola, Gianluca Caridi, Cristina Zennaro, Michele Carraro, Gian Marco Ghiggeri, Giovanni Camussi.   

Abstract

The presence of circulating plasma factors (PF) altering renal permeability to proteins has been previously described in patients with focal segmental glomerulosclerosis (FSGS). Since these patients show reduced nephrin and podocin expression at renal biopsy, we evaluated the effect of serum and PF from patients with FSGS on nephrin and podocin expression in human podocytes. We studied 7 sera from patients with steroid-resistant FSGS, 3 from patients with nephrotic syndrome caused by non-immune disease, and 6 from healthy subjects. PF was prepared from plasmapheresis eluates of 2 patients with post-transplant recurrence of FSGS. Purification procedure was based on protein A Sepharose chromatography and differential precipitation in ammonium sulphate. Nephrin and podocin expression was semi-quantitatively evaluated by immunofluorescence. We found that serum and PF from FSGS patients rapidly induced redistribution and loss of nephrin in podocytes. This effect was associated with cytoskeleton redistribution and inhibited by cytochalasin B and sodium azide. On the contrary, podocin expression was unchanged after incubation with serum and PF from FSGS patients for short periods, but markedly reduced at 24 h. Our results demonstrate that serum and PF from FSGS patients may directly affect nephrin and podocin in human podocytes, thus providing new insights into the mechanisms causing proteinuria in FSGS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942677

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

1.  Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.

Authors:  Eun Young Kim; Hila Roshanravan; Stuart E Dryer
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-16       Impact factor: 5.187

2.  Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs.

Authors:  Federica Collino; Maria Chiara Deregibus; Stefania Bruno; Luca Sterpone; Giulia Aghemo; Laura Viltono; Ciro Tetta; Giovanni Camussi
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

3.  Recurrent focal segmental glomerulosclerosis: a discrete clinical entity.

Authors:  Elena Torban; Martin Bitzan; Paul Goodyer
Journal:  Int J Nephrol       Date:  2012-01-11

4.  Podocyte expression of membrane transporters involved in puromycin aminonucleoside-mediated injury.

Authors:  Cristina Zennaro; Maria Pia Rastaldi; Lorella Pascolo; Marco Stebel; Elisa Trevisan; Mary Artero; Claudio Tiribelli; Vittorio Di Maso; Michele Carraro
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

5.  A nanoporous surface is essential for glomerular podocyte differentiation in three-dimensional culture.

Authors:  Cristina Zennaro; Maria Pia Rastaldi; Gerald James Bakeine; Riccarda Delfino; Federica Tonon; Rossella Farra; Gabriele Grassi; Mary Artero; Massimo Tormen; Michele Carraro
Journal:  Int J Nanomedicine       Date:  2016-09-30

6.  Nephrin Loss Can Be Used to Predict Remission and Long-term Renal Outcome in Patients With Minimal Change Disease.

Authors:  Nina A van de Lest; Malu Zandbergen; Daphne H T IJpelaar; Ron Wolterbeek; Jan A Bruijn; Ingeborg M Bajema; Marion Scharpfenecker
Journal:  Kidney Int Rep       Date:  2017-09-28

7.  Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS.

Authors:  Sophie Doublier; Cristina Zennaro; Luca Musante; Tiziana Spatola; Giovanni Candiano; Maurizio Bruschi; Luca Besso; Massimo Cedrino; Michele Carraro; Gian Marco Ghiggeri; Giovanni Camussi; Enrico Lupia
Journal:  PLoS One       Date:  2017-11-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.